Division of Allergy, University of Rochester Medical Center, Rochester, New York, United States of America.
PLoS One. 2012;7(4):e35356. doi: 10.1371/journal.pone.0035356. Epub 2012 Apr 18.
The induction of a broadly neutralizing antibody (BNAb) response against HIV-1 would be a desirable feature of a protective vaccine. Vaccine strategies thus far have failed to elicit broadly neutralizing antibody responses; however a minority of HIV-infected patients do develop circulating BNAbs, from which several potent broadly neutralizing monoclonal antibodies (mAbs) have been isolated. The findings that several BNmAbs exhibit autoreactivity and that autoreactive serum antibodies are observed in some HIV patients have advanced the possibility that enforcement of self-tolerance may contribute to the rarity of BNAbs. To examine the possible breakdown of tolerance in HIV patients, we utilized the 9G4 anti-idiotype antibody system, enabling resolution of both autoreactive VH4-34 gene-expressing B cells and serum antibodies. Compared with healthy controls, HIV patients had significantly elevated 9G4+ serum IgG antibody concentrations and frequencies of 9G4+ B cells, a finding characteristic of systemic lupus erythematosus (SLE) patients, both of which positively correlated with HIV viral load. Compared to the global 9G4-IgD--memory B cell population, the 9G4+IgD--memory fraction in HIV patients was dominated by isotype switched IgG+ B cells, but had a more prominent bias toward "IgM only" memory. HIV envelope reactivity was observed both in the 9G4+ serum antibody and 9G4+ B cell population. 9G4+ IgG serum antibody levels positively correlated (r = 0.403, p = 0.0019) with the serum HIV BNAbs. Interestingly, other serum autoantibodies commonly found in SLE (anti-dsDNA, ANA, anti-CL) did not correlate with serum HIV BNAbs. 9G4-associated autoreactivity is preferentially expanded in chronic HIV infection as compared to other SLE autoreactivities. Therefore, the 9G4 system provides an effective tool to examine autoreactivity in HIV patients. Our results suggest that the development of HIV BNAbs is not merely a consequence of a general breakdown in tolerance, but rather a more intricate expansion of selective autoreactive B cells and antibodies.
HIV-1 广谱中和抗体(BNAb)的诱导将是保护性疫苗的理想特征。迄今为止,疫苗策略未能引发广泛的中和抗体反应;然而,少数 HIV 感染患者确实会产生循环 BNAb,从中分离出几种有效的广谱中和单克隆抗体(mAb)。有研究发现,一些 BNmAbs 具有自身反应性,并且一些 HIV 患者中存在自身反应性血清抗体,这使得自我耐受的实施可能有助于 BNAb 的稀有性成为可能。为了研究 HIV 患者中可能存在的耐受破坏,我们利用了 9G4 抗独特型抗体系统,能够解析表达 VH4-34 基因的自身反应性 B 细胞和血清抗体。与健康对照组相比,HIV 患者的 9G4+血清 IgG 抗体浓度和 9G4+B 细胞频率显著升高,这一发现与系统性红斑狼疮(SLE)患者的特征一致,两者均与 HIV 病毒载量呈正相关。与全球 9G4-IgD-记忆 B 细胞群体相比,HIV 患者的 9G4+IgD-记忆亚群主要由同种型转换的 IgG+B 细胞组成,但更偏向于“仅 IgM”记忆。在 9G4+血清抗体和 9G4+B 细胞群体中均观察到 HIV 包膜反应性。9G4+IgG 血清抗体水平与血清 HIV BNAb 呈正相关(r=0.403,p=0.0019)。有趣的是,SLE 中常见的其他血清自身抗体(抗 dsDNA、ANA、抗 CL)与血清 HIV BNAb 不相关。与其他 SLE 自身反应性相比,9G4 相关的自身反应性在慢性 HIV 感染中优先扩增。因此,9G4 系统为研究 HIV 患者的自身反应性提供了有效的工具。我们的结果表明,HIV BNAb 的产生不仅仅是耐受普遍破坏的结果,而是更复杂的选择性自身反应性 B 细胞和抗体的扩增。